139 related articles for article (PubMed ID: 32398249)
21. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography.
Ersoy L; Ristau T; Kirchhof B; Liakopoulos S
Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):889-97. PubMed ID: 24271025
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of ranibizumab for pregnant women in idiopathic choroidal neovascularization.
Jouve L; Akesbi J; Nordmann JP
Acta Ophthalmol; 2015 Nov; 93(7):e597-8. PubMed ID: 25483229
[No Abstract] [Full Text] [Related]
23. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.
Papastefanou VP; Pefkianaki M; Al Harby L; Arora AK; Cohen VM; Andrews RM; Sagoo MS
Eye (Lond); 2016 Jun; 30(6):843-9. PubMed ID: 27034203
[TBL] [Abstract][Full Text] [Related]
24. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.
Schmidt-Erfurth U; Vogl WD; Jampol LM; Bogunović H
Ophthalmology; 2020 Sep; 127(9):1211-1219. PubMed ID: 32327254
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma.
Song WK; Koh HJ; Kwon OW; Byeon SH; Lee SC
Acta Ophthalmol; 2009 Feb; 87(1):100-1. PubMed ID: 19178391
[No Abstract] [Full Text] [Related]
26. Systemic steroids for the management of choroidal neovascular membrane with pigment epithelial tear and recalcitrant subretinal fluid.
Bilgic A; Sudhalkar A
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31494592
[TBL] [Abstract][Full Text] [Related]
27. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
28. Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma.
Jang JH; Kim KH; Lee SJ; Park JM
Korean J Ophthalmol; 2012 Dec; 26(6):478-80. PubMed ID: 23204807
[TBL] [Abstract][Full Text] [Related]
29. Choroidal neovascular membrane in a treated choroidal hemangioma.
Nagesha CK; Walinjkar JA; Khetan V
Indian J Ophthalmol; 2016 Aug; 64(8):606-8. PubMed ID: 27688287
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes.
Chan CK; Sarraf D; Abraham P
Eur J Ophthalmol; 2018 Nov; 28(6):677-683. PubMed ID: 29575941
[TBL] [Abstract][Full Text] [Related]
31. Spectral-Domain Optical Coherence Tomography of Polypoidal Choroidal Vasculopathy Associated With Benign Choroidal Nevus.
De Salvo G; Vaz-Pereira S; Sehmi KS; Andrews RM; Sagoo MS
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1062-4. PubMed ID: 26599253
[TBL] [Abstract][Full Text] [Related]
32. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
33. Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease.
Subbiah D; Hashim H; Chew FLM
Ocul Immunol Inflamm; 2020 Oct; 28(7):1149-1151. PubMed ID: 31509457
[TBL] [Abstract][Full Text] [Related]
34. Complications, treatments, and visual prognosis of choroidal osteomas.
Seong HJ; Kim YJ; Choi EY; Lee J; Byeon SH; Kim SS; Koh HJ; Lee SC; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1713-1721. PubMed ID: 34762167
[TBL] [Abstract][Full Text] [Related]
35. Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?
Sharma A; Kumar N; Singh S; Regillo CD; Freund KB
Retina; 2020 Aug; 40(8):1451-1455. PubMed ID: 32568979
[No Abstract] [Full Text] [Related]
36. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
37. Secondary choroidal neovascularization due to choroidal osteoma after 9 years follow-up.
Zhang Y; Fang J; Zhao S; She X; Wang J; Shen L
BMC Ophthalmol; 2021 May; 21(1):242. PubMed ID: 34058993
[TBL] [Abstract][Full Text] [Related]
38. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
39. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
Lee EK; Yu HG
Korean J Ophthalmol; 2019 Jun; 33(3):228-237. PubMed ID: 31179654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
